within Pharmacolibrary.Drugs.ATC.C;

model C03CB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 108 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bumetanide is a potent loop diuretic used primarily for the treatment of edema associated with congestive heart failure, liver cirrhosis, and renal disease, including nephrotic syndrome. Potassium is often co-administered to mitigate hypokalemia caused by bumetanide. This combination is used clinically where both diuretic and potassium supplementation are required, and bumetanide is an approved diuretic agent.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data specific to the bumetanide and potassium combination was found. Estimates are based on published data for bumetanide administered orally in adults with normal renal function.</p><h4>References</h4><ol><li><p>Griffin, M, et al., &amp; Testani, JM (2020). Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> 142(11) 1028–1039. DOI:<a href=&quot;https://doi.org/10.1161/CIRCULATIONAHA.120.045691&quot;>10.1161/CIRCULATIONAHA.120.045691</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32410463/&quot;>https://pubmed.ncbi.nlm.nih.gov/32410463</a></p></li><li><p>Oberbauer, R, et al., &amp; Turnheim, K (1995). Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly. <i>Clinical pharmacology and therapeutics</i> 57(1) 42–51. DOI:<a href=&quot;https://doi.org/10.1016/0009-9236(95)90264-3&quot;>10.1016/0009-9236(95)90264-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7828380/&quot;>https://pubmed.ncbi.nlm.nih.gov/7828380</a></p></li><li><p>Jones, RS, et al., &amp; Morris, ME (2020). Contribution of Monocarboxylate Transporter 6 to the Pharmacokinetics and Pharmacodynamics of Bumetanide in Mice. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 48(9) 788–795. DOI:<a href=&quot;https://doi.org/10.1124/dmd.120.000068&quot;>10.1124/dmd.120.000068</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32587098/&quot;>https://pubmed.ncbi.nlm.nih.gov/32587098</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C03CB02;
